APN-497444 / Atreca - LARVOL DELTA

Atreca Reports Fourth Quarter and Full-Year 2022 Financial Results and ATRC-101 Data Update (GlobeNewswire) - "Additional data from the ongoing study will inform a future decision concerning whether to advance ATRC-101 into Phase 2 studies and in which indications. Atreca expects to report additional data from the Phase 1b study and provide details on its potential Phase 2 development plans by the end of 2023....APN-497444 (‘444) is an Atreca-discovered antibody targeting a novel, tumor-specific glycan.... Atreca expects to nominate a clinical candidate from the program in 2023 and is targeting an IND submission in late 2024....APN-346958 (‘958)...Atreca and Xencor expect to name a candidate from the program in 2023 and target an IND submission by early 2025."

IND • New P2 trial • P1 data • Oncology

Atreca Announces Expansion of Preclinical Pipeline (GlobeNewswire) - "Atreca...announced a licensing agreement with Zymeworks...to utilize their ZymeLink™ technology to develop novel antibody-drug conjugates (ADCs) and declared ATRC-301, an ADC targeting a novel epitope on EphA2, as the Company’s next clinical candidate....'We are targeting one additional Investigational New Drug (IND) application per year beginning with ATRC-301 in the second half of 2023'....Atreca is advancing multiple additional lead-stage programs in oncology, including ADC leads APN-497444 and APN–959038, CD3-engager lead APN-346958, and IL-15 superagonist (SA) conjugate lead APN-541885."

IND • Licensing / partnership • Pipeline update • Oncology